Testosterone and obesity

DM Kelly, TH Jones - Obesity Reviews, 2015 - Wiley Online Library
Testosterone is a key hormone in the pathology of metabolic diseases such as obesity. Low
testosterone levels are associated with increased fat mass (particularly central adiposity) …

Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases

JA Santos-Marcos, M Mora-Ortiz… - Biology of sex …, 2023 - Springer
Metabolic diseases, such as obesity, metabolic syndrome (MetS) and type 2 diabetes (T2D),
are now a widespread pandemic in the developed world. These pathologies show sex …

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

PW Kantoff, CS Higano, ND Shore… - … England Journal of …, 2010 - Mass Medical Soc
Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown
evidence of efficacy in reducing the risk of death among men with metastatic castration …

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and …

GN Levine, AV D'Amico, P Berger, PE Clark, RH Eckel… - Circulation, 2010 - Am Heart Assoc
ADT was first used in prostate cancer for patients with overt metastatic disease, 7 and it
remains the mainstay of therapy for this group. ADT combined with external-beam radiation …

Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review

JR Gardner, PM Livingston, SF Fraser - Journal of Clinical Oncology, 2014 - ascopubs.org
Purpose Androgen-deprivation therapy is a commonly used treatment for men with prostate
cancer; however, the adverse effects can be detrimental to patient health and quality of life …

Metabolic complications of androgen deprivation therapy for prostate cancer

PJ Saylor, MR Smith - The Journal of urology, 2009 - Elsevier
PURPOSE: Androgen deprivation therapy has a variety of well recognized adverse effects
including vasomotor flushing, loss of libido, fatigue, gynecomastia, anemia and …

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study

MT Schweizer, ES Antonarakis, H Wang… - Science translational …, 2015 - science.org
Targeting androgen receptor (AR) axis signaling by disrupting androgen-AR interactions
remains the primary treatment for metastatic prostate cancer. Unfortunately, all men develop …

The metabolic syndrome in cancer survivors

EC De Haas, SF Oosting, JD Lefrandt… - The lancet …, 2010 - thelancet.com
The metabolic syndrome, as a cluster of cardiovascular risk factors, may represent an
important connection between cancer treatment and its common late effect of cardiovascular …

Obesity and male hypogonadism: Tales of a vicious cycle

DF Carrageta, PF Oliveira, MG Alves… - Obesity …, 2019 - Wiley Online Library
Obesity prevalence, particularly in children and young adults, is perilously increasing
worldwide foreseeing serious negative health impacts in the future to come. Obesity is linked …

Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy

EJ Hamilton, E Gianatti, BJ Strauss… - Clinical …, 2011 - Wiley Online Library
Objective Androgen deprivation therapy (ADT) for prostate cancer is associated with
increases in fat mass and risk of type 2 diabetes; however, the relationship between sex …